



ASX Announcement

Replacement of Chairman and Legal Representative to China subsidiary

Melbourne Australia, 8 October 2013: Agenix Limited (ASX: AGX) ("Agenix" or "the Company") wishes to advise that group Chairman and Chief Executive Mr Nicholas Weston has replaced Mr Tang Wen Sen as Chairman and Legal Representative of Agenix Biopharmaceuticals Shanghai Co Ltd ("the Agenix WFOE").

The Company wishes Mr Tang well in his future endeavours.

Mr Weston is a prominent Australian lawyer and biotech executive with strong China experience and will oversee the exit of the Company from China operations to follow the divestment of its AGX-1009 project, a tenofovir prodrug for hepatitis B which recently completed preclinical studies.

For more information please contact:

Gary Taylor
Agenix Limited
Tel: +61 467 559 037